Hold at 5-7% with $94-$95 covered-call overlay; reject fresh Buy at $90.21 per prohibited execution-refinement pattern
The covered-call overlay is chosen over trim-to-underweight for three reasons: (1) the aggressive analyst's structural case has real evidence (gross margin +140 bps to 61.5%, FCF coverage 2x, intact primary trend) that does not justify trimming core franchise exposure; (2) prior 8/12 reflection noted trim theses on quality compounders rarely produce positive alpha; (3) the $89.50-$94.60 range makes $94-$95 covered calls structurally attractive—strike sits above current price (preserves breakout optionality), aligns with failed July peak (high probability of reaching strike), and generates the "underweighted defensive carry" explicitly identified in 8/13 reflection. Key invalidation: daily close below $89.50 with volume >4M challenges structural thesis and triggers reassessment toward trim-to-underweight; close above $95.00 with volume >4M forces reassessment toward Overweight.
| Position | Action |
|---|---|
| Current portfolio weight | Maintain 5-7% exposure |
| Fresh capital addition | Do not execute (prohibited pattern per 8/14 reflection) |
The current pullback is a buying opportunity within an intact multi-year uptrend, with CL trading $4.28 above its 200-day SMA, gross margins expanding 140 basis points, and a DCF showing 30% undervaluation—making it a defensive compounder perfectly suited for the stagflationary macro regime.
| Indicator | Value | Signal |
|---|---|---|
| close | 90.21 | neutral |
| volume | 3,087,630 | neutral |
| 50_sma | 91.26 | bearish |
| 200_sma | 85.93 | bullish |
| 10_ema | 92.02 | bearish |
| rsi | 43.68 | bearish |
| macd | 0.18 | bearish |
| macd_signal | 0.38 | bearish |
| macd_histogram | -0.20 | bearish |
| bollinger_middle | 91.94 | bearish |
| bollinger_upper | 94.27 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed close above $95.00 on volume >4M
Then: Reassess toward Overweight; close short call, re-engage with full sizing
The 'valuation paradox' resolves bullishly—DCF shows 30% undervaluation; P/E ratios misprice long-duration compounders
↩ rebuts: “Bear's headline '6% overvalued' narrative”
EV: +5-7% upside to fair value (DCF) · concedes: RSI at 43.68 is technically sloppy on the 4-hour chart; MACD has crossed over with red expanding histogram; Lower highs sequence since July peak; Input cost risk from palm oil and packaging exists
CL's stock is exhibiting a clear sequence of deteriorating technical momentum and full valuation that makes it a SELL at current levels, despite solid long-term fundamentals.
· concedes: 200 SMA long-term uptrend is intact as a longer-term framing; Gross margin expanded 140 bps in Q2 (pricing-driven, not volume-driven, but still positive); Operating income did recover to Q4 2025 levels; DCF methodology is valid for cash-generative businesses in theory; CL's brand position in oral care is #1 globally
→ vs conservative: Seven lower highs since July represent distribution thesis, but lower highs came after 27% surge from $75 to $95—context matters, and contraction volume on decline proves smart money is not distributing
→ vs conservative: MACD bearish crossover at 0.18 represents end of momentum flush, not beginning; momentum reset is 88% complete from peak
→ vs neutral: Waiting for RSI 30 or 50 SMA reclaim at $91.26 means chasing 5% higher and giving up asymmetry; CL rarely offers textbook entries
→ vs neutral: Operating margin contraction is strategic reinvestment, not structural deterioration; gross margin expansion to 61.5% is highest in data set
→ vs neutral: KMB guidance cut creates rotational bid into CL with stronger fundamentals, not read-across risk away from consumer staples
| bollinger_lower | 89.62 | bearish |
| vwma | 92.02 | bearish |
| atr | 2.18 | neutral |
Support: 89.62 · 88.55 · 85.93 | Resistance: 92 · 91.94 · 94.27
CL exhibits short-term bearish momentum within an intact long-term uptrend. Price closed below 50 SMA and 10 EMA with bearish MACD crossover and negative expanding histogram. The $89.62 lower Bollinger Band was pierced intraday (low of $89.47) before recovery. Long-term structure remains bullish with price well above 200 SMA at $85.93. Recommendation: HOLD existing positions with defensive stops around $88.55; WAIT for new entries until price reclaims $92.00 on volume or shows oversold divergence.
Market Cap
$71.91 billion
52-Week High
$99.33
52-Week Low
$74.55
50-Day Moving Average
$91.46
200-Day Moving Average
$86.74
Beta
0.327
Trailing PE
35.5x
Forward PE
22.0x
PEG Ratio
1.77
Price/Book
304.8x
EPS TTM
$2.54
Forward EPS
$4.10
Dividend Yield
2.31%
Revenue TTM
$21.05B
Gross Profit TTM
$12.72B
EBITDA TTM
$4.98B
Net Income TTM
$2.04B
Gross Margin TTM
60.4%
Operating Margin TTM
20.97%
Net Profit Margin TTM
9.68%
EBITDA Margin TTM
23.7%
Return on Assets
15.84%
Return on Equity
267%
Q2 2025 Revenue
$5,110M
Q2 2025 Gross Profit
$3,069M
Q2 2025 Operating Income
$1,080M
Q2 2025 Net Income
$743M
Q2 2025 Diluted EPS
$0.91
Q3 2025 Revenue
$5,131M
Q3 2025 Gross Profit
$3,049M
Q3 2025 Operating Income
$1,059M
Q3 2025 Net Income
$735M
Q3 2025 Diluted EPS
$0.91
Q4 2025 Revenue
$5,230M
Q4 2025 Gross Profit
$3,146M
Q4 2025 Operating Income
$1,019M
Q4 2025 Net Income
($37M)
Q4 2025 Diluted EPS
($0.05)
Q1 2026 Revenue
$5,324M
Q1 2026 Gross Profit
$3,226M
Q1 2026 Operating Income
$964M
Q1 2026 Net Income
$646M
Q1 2026 Diluted EPS
$0.80
Q2 2026 Revenue
$5,361M
Q2 2026 Gross Profit
$3,296M
Q2 2026 Gross Margin
61.5%
Q2 2026 Operating Income
$1,016M
Q2 2026 Net Income
$693M
Q2 2026 Diluted EPS
$0.86
Total Assets Q2 2026
$16,790M
Total Liabilities Q2 2026
$16,224M
Stockholders Equity Q2 2026
$236M
Treasury Stock Q2 2026
$28,931M
Retained Earnings Q2 2026
$27,085M
Cash Equivalents Q2 2026
$1,370M
Total Debt Q2 2026
$7,857M
Net Debt Q2 2026
$6,487M
Net Debt Q3 2025
$7,140M
Net Debt/EBITDA
1.3x
Inventory Q2 2026
$2,181M
Receivables Q2 2026
$1,962M
Goodwill Intangibles Q2 2026
$4,595M
Current Ratio Q2 2026
1.026
Operating Cash Flow TTM
$4,456M
Free Cash Flow TTM
$3,458M
CapEx TTM
$598M
CapEx as Percent of Revenue
2.8%
Dividends Paid TTM
$1,822M
Buybacks TTM
$1,291M
Capital Return Yield
4.3%
Total Shareholder Return Yield
4.1%
Diluted Shares Outstanding YoY Change
813M to 802M
Annual Interest Expense
$620M
Strengths
Concerns
Colgate-Palmolive is a high-quality, defensive consumer staples franchise executing well on operational turnaround following a one-time Q4 2025 charge, with improving margins, revenue growth, and deleveraging. The valuation is full but not extreme on a forward basis (22.0x forward PE), and the strong FCF base ($3.46B TTM) supports both the dividend (2.31% yield) and aggressive capital returns ($3.11B TTM). Best suited for income-focused, risk-averse, or hedged long strategies with a preference for entry on minor pullbacks toward the 50-day MA ($91.46) or 200-day MA ($86.74).
Macro: Geopolitical escalation is the dominant macro shock — US–Iran ceasefire expired, Strait of Hormuz disruption re-pricing ~600,000 bpd of oil supply through year-end 2026; Polymarket implies 1% chance of normalization by Aug 31, 10% by Sep 30, 46% Iran charges transit fees by Oct 31. Bond market screaming stagflation: 30-year Treasury at highest level since 2007. Fed pricing zero cuts in 2026 (85% probability). US recession risk low (8%), Japan elevated (49% and rising), UK moderate (11%). Oil-driven inflation is the binding constraint on global growth; Asian shares mixed, commodities mixed.